Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Phathom Pharmaceuticals, Inc. (PHAT)

Phathom Pharmaceuticals Q3 revenue rises 71% to $84.7 million; guidance reaffirmed

Positive Impact 3 of 5 earnings Written later

Phathom Pharmaceuticals reported third quarter 2026 net revenue of $84.7 million, up 71% from $49.5 million a year earlier, and a net loss of $13.9 million, narrowed from $30.0 million. The company reaffirmed its full-year 2026 net revenue guidance of $310–325 million and said it generated positive operating cash flow for the second consecutive quarter.

Key points

  • Q3 2026 net revenue was $84.7 million, up $35.2 million from $49.5 million in Q3 2025.
  • Q3 2026 net loss was $13.9 million, compared with $30.0 million in Q3 2025; non-GAAP adjusted net income was $3.0 million.
  • FY 2026 net revenue guidance of $310–325 million was maintained, not changed.
  • Cash and cash equivalents were $184.6 million as of September 30, 2026.

The filing

CompanyPhathom Pharmaceuticals, Inc. (PHAT)
Form8-K, current report
Filed with the SECOct 29, 2026, 7:05 AM ET
Accession number0001193125-26-436959

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.